<SEC-DOCUMENT>0001193125-21-195398.txt : 20210622
<SEC-HEADER>0001193125-21-195398.hdr.sgml : 20210622
<ACCEPTANCE-DATETIME>20210621195404
ACCESSION NUMBER:		0001193125-21-195398
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210621
FILED AS OF DATE:		20210622
DATE AS OF CHANGE:		20210621

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		211032613

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		612 9276 1224

	MAIL ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d147819d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated June 21, 2021 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP
LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 12, 95 Pitt Street </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Sydney, 2000 New South Wales, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
20-F&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the
registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the
information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d147819dex991.htm">Immutep to Evaluate Efti in Triple Combination Therapy Phase I Study with Chemotherapy and an anti-PD-1 Therapy </A></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: June 21, 2021 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d147819dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g147819rt.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ASX/Media Release </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Immutep to Evaluate Efti in Triple Combination Therapy Phase I Study </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>with Chemotherapy and an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> Therapy </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">New Phase I clinical trial, called <FONT STYLE="white-space:nowrap">INSIGHT-003,</FONT> in patients with various
solid tumours </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Expands the evaluation of efti into a triple combination therapy of efti, chemotherapy and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">First patient in expected in Q3 of calendar year 2021, with initial interim results expected in 2022
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SYDNEY, AUSTRALIA &#150; 21</B><B></B><B>&nbsp;June</B><B> 2021 &#150;</B> <U>Immutep Limited</U> (ASX: IMM; NASDAQ: IMMP)
(&#147;Immutep&#148; or &#147;the Company&#148;), a biotechnology company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> related immunotherapy treatments for cancer and autoimmune disease, announces it has signed an agreement to
commence a new Phase I trial, called <FONT STYLE="white-space:nowrap">INSIGHT-003,</FONT> to evaluate the combination of lead product candidate eftilagimod alpha (&#147;efti&#148; or &#147;IMP321&#148;) in conjunction with an existing approved
standard of care therapy consisting of a chemotherapy agent and an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">INSIGHT-003</FONT> will be an investigator-initiated trial conducted by the Institute of Clinical Cancer Research IKF at
Krankenhaus Nordwest in Frankfurt. The trial will be run as an amendment to the protocol of the ongoing INSIGHT trial as the third arm (Stratum C) with Prof. Dr.&nbsp;Salah-Eddin Al-Batran as lead investigator. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Up to 20 patients with various solid tumours will be recruited to participate in the trial. Patients will receive 30 mg doses of efti every two weeks for 24
weeks in conjunction with standard of care chemotherapy plus <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy. Thereafter, patients will enter a maintenance phase and receive either efti alone or in
double or continued triple combination with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy. The trial will assess the safety, tolerability and initial efficacy of the combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All regulatory and ethical approvals have been received, enabling recruitment to commence. The first patient is expected to be enrolled in Q3 of calendar year
2021, with first interim results expected in 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Commenting on the new trial, Immutep CEO Marc Voigt said:</B> &#147;Testing efti as part of a
triple combination therapy is an important and exciting expansion of our development program. Efti activates the immune system and could bring a significant benefit to multiple approved standard of care therapies and experimental therapies. Together
with our other trials, we are building a very robust pool of data to understand how efti can ultimately improve outcomes for cancer patients.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Prof. Salah-Eddin Al-Batran, Lead Investigator of the INSIGHT trial said:</B> &#147;There is a solid scientific rationale for adding efti to certain
existing <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> chemotherapy plus <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> regimen in a triple combination
approach and we are excited about the possibility of generating the first safety and efficacy data for the <FONT STYLE="white-space:nowrap">efti-add-on</FONT> triple combination in our INSIGHT trial platform.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>, Level 12, 95 Pitt Street, Sydney NSW 2000 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g147819rt.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement was authorised for release by the board of Immutep Limited. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immutep </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a globally active biotechnology
company that is a leader in the development of <FONT STYLE="white-space:nowrap">LAG-3</FONT> related immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to
bring innovative treatment options to market for patients and to maximize value to shareholders. Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep&#146;s current lead product candidate is eftilagimod alpha (&#147;efti&#148; or &#147;IMP321&#148;), a soluble
<FONT STYLE="white-space:nowrap">LAG-3</FONT> fusion protein <FONT STYLE="white-space:nowrap">(LAG-3Ig),</FONT> which is a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> antigen presenting cell (APC)
activator being explored in cancer and infectious disease. Immutep is also developing an agonist of <FONT STYLE="white-space:nowrap">LAG-3</FONT> (IMP761) for autoimmune disease. Additional <FONT STYLE="white-space:nowrap">LAG-3</FONT> products,
including antibodies for immune response modulation, are being developed by Immutep&#146;s large pharmaceutical partners. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further information can be
found on the Company&#146;s website <U>www.immutep.com</U> or by contacting: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Catherine Strong, Citadel-MAGNUS </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)406 759 268;
<U>cstrong@citadelmagnus.com</U> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Media: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tim
McCarthy, LifeSci Advisors </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (212) 915.2564;&nbsp;<U>tim@lifesciadvisors.com</U> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>,
Level 12, 95 Pitt Street, Sydney NSW 2000 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g147819rt.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g147819rt.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #__@ ?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP!#  (! 0(! 0(" @(" @(" P4# P,# P8$! ,%!P8'!P<&
M!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_VP!# 0(" @,# P8#
M P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# S_P  1" ![ R # 2(  A$! Q$!_\0 'P   04! 0$! 0$
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(\,WL4UJH-SL'G*V[ISCCI6']HTMG=/M;4XX\3X1OE:DI=$XN[]#[2HKX/\
M#7[>7Q#^%GB:.V\?Z;=20SD_Z/+&+:81CK(N!AL9'>OJCQY\7ET[]FO5O&VC
MR-(L>BR:I;%CV6/> ?>MZ.*IU?AW.[+\VP^,<HTKJ4=TU9J_D>D4V3.QMO7'
M%?#/_!.'_@H%XN_:L^-=]HNM-&FG0Z.U_&JXW;MX4= /6OH#]N;XW:K^S[^S
MAK'BC1E!O;-H8T,A&!N<+GG/K70>H>O74ZK'(SY_=*21_>P,U\J_!3_@I]9?
M&[]I.+P#I_A62WC:>6"34)+H?*4!/";>^/6M_P#X)]?M':]^U'\#-9USQ JQ
MWUEJ<MHNP@ H(4;L!_>K\VOA/XZ\1?##]K.\UCPQ83:QK5GJ%P\5K;KYDCJ=
MPZ 'UH _;+3AA&^8LN>"3R:L5\0_LM_M:?&KXC?'/P[I/BKPCK6E:%=23+?3
M26++'&!$Y3+%1_$%''K7T-^U7^U5H_[*?PMF\0:POG3;_+M+-9,27+YZ9[ *
M"23Z4 >L45^9-_\ MU_M&_M :F_B7X>:+>V/A9#Q!#:QW*NJ]<2$<D^@S7JG
M[''_  5 N-?\6_\ "'_%*WNM%UZYF$-G<3Q>6KR$@>4Z@#:W(()&#F@#[BJ.
M==Z >XKYA_X*+?MJ:M^R1HGAMM(MH;J37))HVDDE"B#8%(['/6OE?2?VP_VI
M_%\*Z]IMCJTFAS8DA6#2XY(Y(SQN#XR<=: /TB^*OP]A^)WP]U?0I9/)758&
MB\S&?+;'!_#%? =KX3O/V2/'6H)J-UJ47B"P1SI4=LA-I>1@':\C9X)YR*[3
M]F/_ (*P27OC:S\&_$?2;NQU22Y^S-J& J*YZ!TXV\\=*^U-1\.Z-XUTQ7O+
M.QU*SN%ROFQ+(LJMTZCI7)BL+[5)IV:ZGCYEE,<5.-:+Y9QV9^;6H_'CQI\:
MO%JK=+)JTUQ'Y,-HB'R$8G&22>*^T?V)/V=KSX$>"[IM5$:ZMJOER3I&=RH
M#@9]LFO4O#7PR\.^$MS:7H>EZ?N.28+9(R?R%;P4 ]*RPN!]G-U)N[.3*\@^
MK5?K%>?/4[B;OFQ2T8YHKT#Z,**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M&7<N#R#P:QX/A]H=L9?+TG3T\[(DQ"OSYZY^M;%% %3^P;,+;C[+#BS_ -1\
MH_<\8^7TX..*HK\/-#35$OO[)L/MD;F19O)'F*QZD'KDULT4 9^L>%M.\0VW
MDZA9V][%G.V=!(!^=6++2;;3K2.""&.*&/[B*N%3Z"K%% %&/PW8PK&([6&,
M13-<)L7;MD;.YA[G)R?<TZ70+*:Z69K6$S*"%DVC<H/7!_$U<HH ST\*Z?';
MR0I:0QQS*4=57:'!))!]>23^-1ZMX*TG77C:]T^TNC&GEKYL8;"^G/TK4HH
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M1_;EG_S]0_\ ?RBZ[A[1>7WHO>8OK1YB^M4?[<L_^?J'_OY1_;EG_P _4/\
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MY1_;EG_S]0_]_*+KN'M%Y?>B]YB^M'F+ZU1_MRS_ .?J'_OY1_;EG_S]0_\
M?RBZ[A[1>7WHO>8OK1YB^M4?[<L_^?J'_OY1_;EG_P _4/\ W\HNNX>T7E]Z
M+WF+ZT>8OK5'^W+/_GZA_P"_E']N6?\ S]0_]_*+KN'M%Y?>B]YB^M'F+ZU1
M_MRS_P"?J'_OY1_;EG_S]0_]_*+KN'M%Y?>B]YB^M'F+ZU1_MRS_ .?J'_OY
M1_;EG_S]0_\ ?RBZ[A[1>7WHO>8OK1YB^M4?[<L_^?J'_OY1_;EG_P _4/\
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MY1_;EG_S]0_]_*+KN'M%Y?>B]YB^M'F+ZU1_MRS_ .?J'_OY1_;EG_S]0_\
M?RBZ[A[1>7WHO>8OK1YB^M4?[<L_^?J'_OY1_;EG_P _4/\ W\HNNX>T7E]Z
M+WF+ZT>8OK5'^W+/_GZA_P"_E']N6?\ S]0_]_*+KN'M%Y?>B]YB^M'F+ZU1
M_MRS_P"?J'_OY1_;EG_S]0_]_*+KN'M%Y?>B]YB^M'F+ZU1_MRS_ .?J'_OY
M1_;EG_S]0_\ ?RBZ[A[1>7WHO>8OK1YB^M4?[<L_^?J'_OY1_;EG_P _4/\
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M57Z2_9U_N_K1]G7^[^M']DT^[#_4[#_\_9_>?FU_PI#XY?\ /GXH_P# P_\
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M /%5^DOV=?[OZT?9U_N_K1_9-/NP_P!3L/\ \_9_>?FU_P *0^.7_/GXH_\
M P__ !5'_"D/CE_SY^*/_ P__%5^DOV=?[OZT?9U_N_K1_9-/NP_U.P__/V?
MWGYM?\*0^.7_ #Y^*/\ P,/_ ,51_P *0^.7_/GXH_\  P__ !5?I+]G7^[^
MM'V=?[OZT?V33[L/]3L/_P _9_>?FU_PI#XY?\^?BC_P,/\ \51_PI#XY?\
M/GXH_P# P_\ Q5?I+]G7^[^M'V=?[OZT?V33[L/]3L/_ ,_9_>?FU_PI#XY?
M\^?BC_P,/_Q5'_"D/CE_SY^*/_ P_P#Q5?I+]G7^[^M'V=?[OZT?V33[L/\
M4[#_ //V?WGYM?\ "D/CE_SY^*/_  ,/_P 51_PI#XY?\^?BC_P,/_Q5?I+]
MG7^[^M'V=?[OZT?V33[L/]3L/_S]G]Y^;7_"D/CE_P ^?BC_ ,##_P#%4?\
M"D/CE_SY^*/_  ,/_P 57Z2_9U_N_K1]G7^[^M']DT^[#_4[#_\ /V?WGYM?
M\*0^.7_/GXH_\##_ /%4?\*0^.7_ #Y^*/\ P,/_ ,57Z2_9U_N_K1]G7^[^
MM']DT^[#_4[#_P#/V?WGYM?\*0^.7_/GXH_\##_\51_PI#XY?\^?BC_P,/\
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5G7^[^M']DT^[#_4[#_\ /V?WG__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
